Failure to suppress markers of bone turnover on first line hormonal therapy for metastatic prostate cancer is associated with shorter time to skeletal related event
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC)
Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis
A Phase II Hoosier Oncology Group Study of Vinorelbine and Estramustine Phosphate in Hormone Refractory Prostate Cancer
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer
Phase III Trial of Cyclophosphamide Versus Cyclophosphamide, Doxorubicin and Methotrexate in Hormone-Refractory Prostatic Cancer
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy
Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
A Phase II Trial of Olanzapine, Dexamethasone and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Trial of Antidepressants for Mildly Depressed Cancer Patients Should Have Been Reported in a Manner Allowing Independent Evaluation of Investigators’ Claims
Assessment of Quality of Life in Outpatients with Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being
A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain
Daily Oral Etoposide Plus Ifosfamide Plus Cisplatin for Previously Treated Recurrent Small-Cell Lung Cancer
A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic non-Hodgkin’s Lymphomas
A Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine Alone in Patients with Metastatic Melanoma
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes
Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer
Gefitinib plus Celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Gefitinib in Patients with Chemo-sensitive and Chemo-refractory Relapsed Small Cell Cancers: A Phase II Trial
Randomized Phase II Trial Comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-small Cell Lung Cancer Previously Treated with Chemotherapy
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC: A Hoosier Oncology Group (HOG) phase II study
A Phase II Study of Gemcitabine Plus Paclitaxel in Patients With Previously Untreated Stage IIIb and IV Non-Small Cell Lung Cancer
Etoposide, Ifosfamide and Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer (SCLC): A Phase II study
Maintenance Daily Oral Etoposide versus No Further Therapy Following Induction Chemotherapy with Etoposide plus Ifosfamide plus Cisplatin in Extensive Small-Cell Lung Cancer: A Randomized Trial
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
A Phase II Trial of CODE (Cisplatin, Vincristine, Doxorubicin, Etoposide) Plus Granulocyte-Colony Stimulating Factor (G-CSF) in Advanced Non-Small Cell Lung Cancer
